Search

Search Constraints

You searched for: Author/Creator Egan, Michael F.

Search Results

1. [O2–09–01]: ACUTE ADMINISTRATION OF A BACE INHIBITOR IN HEALTHY HUMANS RESULTS IN A SIGNIFICANT REDUCTION OF Aβ OLIGOMERS IN CEREBROSPINAL FLUID. (1st July 2017)

2. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Issue 1 (6th March 2017)

3. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Issue 11 (13th October 2020)

4. FTS3‐01‐05: FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE‐3 TRIAL OF VERUBECESTAT IN PRODROMAL AD. (1st July 2019)

5. Longitudinal investigation for enhancing Down Syndrome Research (LIFE‐DSR) Study: Tau PET and CSF sub‐studies. (1st February 2022)

6. Longitudinal investigation for enhancing Down Syndrome Research (LIFE‐DSR) Study: Tau PET and CSF sub‐studies. (December 2021)

7. O3‐10‐02: VERUBECESTAT‐INDUCED BRAIN VOLUME LOSS OCCURS RAPIDLY AND ONLY IN AMYLOID‐ENRICHED BRAIN REGIONS IN EPOCH, A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE PATIENTS. (1st July 2019)

8. P1‐042: NEUROFIBRILLARY TANGLE IMAGING WITH [18F]MK‐6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE PATIENTS. (1st July 2019)

9. P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS. (1st July 2019)

10. P3‐040: VERUBECESTAT PHARMACOKINETIC AND EXPOSURE‐RESPONSE RESULTS FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE. (1st July 2019)